News & Updates

Addressing treatment complexity in CKD with early initiation of empagliflozin

Polypharmacy is a well-recognized challenge in chronic kidney disease (CKD) management, driving nonadherence and accelerating disease progression. In an interview with MIMS Doctor, Professor Takashi Yokoo of Jikei University, Japan, discussed how multifunctional sodium-glucose cotransporter-2 inhibitors (SGLT2i) help simplify treatment regimens based on his clinical experience with empagliflozin in patients with complex clinical profiles.

Declining exercise tolerance may signal COPD progression

Decreasing exercise tolerance over 3 years is linked to accelerated lung function decline and air trapping progression in patients with mild-to-moderate chronic obstructive pulmonary disease (COPD), according to a study.

Hydroxychloroquine does little to prevent recurrent miscarriage

Treatment with hydroxychloroquine does not appear to improve the chances of livebirth for women with a history of three consecutive miscarriages, according to a phase III study.

Ambient air pollution ups ARDS, mortality risks in COVID-19 patients

Short- and long-term exposure to ambient air pollution may worsen COVID-19 outcomes, including acute respiratory distress syndrome (ARDS) and mortality, suggests a study.

Standardized terminology vital in team-based rheumatology care models

In team-based rheumatology care models, variations exist in team composition, collaboration, and terminology. These models often produce outcomes similar, and at times superior, to comparator care, results of a scoping review have shown.

Upadacitinib tied to better survival vs tofacitinib in MDA5+DM-ILD

Upadacitinib demonstrates its noninferiority to tofacitinib in improving lung transplantation-free survival (LTFS) at 6 months among patients with anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis with interstitial lung disease (MDA5+DM-ILD), reports a study.

Statins may protect against site-specific cancers

Statin use may reduce the risk of cancer at several sites, including the liver, lung, colon, and rectum, especially for individuals with diabetes, as shown in a retrospective study.

Optimizing frontline CLL therapy with next-generation BTKIs